American Journal of Clinical Nutrition, Vol 51, 407-410, Copyright © 1990 by The American Society for Clinical Nutrition, Inc

ORIGINAL RESEARCH COMMUNICATIONS

Plasma and red blood cell carnitine and carnitine esters during L- carnitine therapy in hemodialysis patients

C Wanner, B Wackerle, H Boeckle, P Schollmeyer and WH Horl
Department of Medicine, University of Freiburg, FRG.

Plasma and red blood cell (RBC) carnitine and acylcarnitines were determined in 20 hemodialysis (HD) patients during three different L- carnitine dosages (1, 5, and 15 mg/kg body wt), each for 3 mo. Before L- carnitine treatment, free carnitine was significantly lowered in plasma but elevated in RBCs compared with healthy subjects. Short-chain acylcarnitines were elevated in plasma and normal in RBCs. HD therapy decreased plasma free and acylcarnitines markedly but did not influence RBC values. Low-dose L-carnitine treatment normalized both plasma- and RBC-free carnitine. Dosages of 5 and 15 mg/kg body wt increased plasma and intracellular carnitine and carnitine esters impressively. Plasma and RBC carnitine fractions remained elevated even after a 6-wk washout period. Low-dose L-carnitine treatment is sufficient to correct disturbed plasma and RBC carnitine and carnitine esters of HD patients. Elevated RBC carnitine esters decreased very slowly, suggesting low RBC carnitine turnover. Carnitine overdosage should be prevented in those patients who benefit from carnitine therapy.

This article has been cited by other articles:

				Y. Kitamura, K. Satoh, T. Satoh, M. Takita, and A. Matsuura Effect of L-carnitine on erythroid colony formation in mouse bone marrow cells Nephrol. Dial. Transplant., May 1, 2005; 20(5): 981 - 984. [Abstract] [Full Text] [PDF]

				J. Bommer Saving erythropoietin by administering L-carnitine? Nephrol. Dial. Transplant., December 1, 1999; 14(12): 2819 - 2821. [Full Text] [PDF]